Koers PledPharma AB (publ) Nasdaq Stockholm
Aandelen
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
||
- SEK | - |
Omzet 2024 * | 70,5 mln. 6,5 mln. 6,04 mln. | Omzet 2025 * | 511 mln. 47,11 mln. 43,75 mln. | Marktkapitalisatie | 1,83 mld. 169 mln. 157 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -305 mln. -28,13 mln. -26,13 mln. | Nettowinst (verlies) 2025 * | 175 mln. 16,14 mln. 14,99 mln. | EV/omzet 2024 * | 27,3 x |
Nettoschuld 2024 * | 87,22 mln. 8,04 mln. 7,47 mln. | Nettoliquiditeiten 2025 * | 119 mln. 10,97 mln. 10,19 mln. | EV/omzet 2025 * | 3,36 x |
K/w-verhouding 2024 * |
-6,6
x | K/w-verhouding 2025 * |
9,17
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 72,61% |
Recentste transcriptie over PledPharma AB (publ)
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 48 | 16-06-17 | |
Yilmaz Mahshid
DFI | Director of Finance/CFO | 45 | 31-12-17 |
Chief Tech/Sci/R&D Officer | - | 05-05-22 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Mats Blom
CHM | Chairman | 59 | 01-04-21 |
Director/Board Member | 50 | 01-01-20 | |
Thomas Lönngren
BRD | Director/Board Member | 73 | 01-04-21 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+3,91% | 109 mld. | |
+10,87% | 105 mld. | |
+1,28% | 22,25 mld. | |
-13,14% | 22,09 mld. | |
-7,05% | 18,68 mld. | |
-38,36% | 17,58 mld. | |
-10,66% | 16,85 mld. | |
+3,75% | 13,76 mld. | |
+36,70% | 12,46 mld. |
- Beurs
- Aandelen
- Koers EGTX
- Koers